Cargando…

Humoral and T Cell Immune Responses to Sars-Cov-2 Vaccination in Hematopoietic Cell Transplant Recipients

Background. Hematopoietic cell transplant (HCT) recipients who develop coronavirus disease 2019 (COVID-19), have dismal prognosis with approximately 20% mortality. Given the lack of a specific and effective therapy, the availability of various vaccination platforms against SARS-CοV-2 has generated o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gavriilaki, Eleni, Papadopoulou, Anastasia, Touloumenidou, Tasoula, Stavridou, Fani, Koravou, Evdoxia, Giannaki, Maria, Papalexandri, Apostolia, Karavalakis, Georgios, Batsis, Ioannis, Kourelis, Andreas, Chatzopoulou, Fani, Chatzidimitriou, Dimitrios, Sotiropoulos, Damianos, Yannaki, Evangelia, Sakellari, Ioanna, Anagnostopoulos, Achilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. Published by Elsevier Inc. 2021
Materias:	722.Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701499/ http://dx.doi.org/10.1182/blood-2021-149399

Ejemplares similares

Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients
por: Gavriilaki, Eleni, et al.
Publicado: (2022)

Immune Response of Adult Sickle Cell Disease Patients after COVID-19 Vaccination: The Experience of a Greek Center
por: Varelas, Christos, et al.
Publicado: (2022)

Targeted genotyping of COVID-19 patients reveals a signature of complement C3 and factor B coding SNPs associated with severe infection
por: Tsiftsoglou, Stefanos A., et al.
Publicado: (2023)

Thrombotic Microangiopathy Variants Are Independently Associated with Critical Disease in COVID-19 Patients
por: Gavriilaki, Eleni, et al.
Publicado: (2020)

Endothelial and Complement Activation As Predictors of Survival in Adult Allogeneic Hematopoietic Cell Transplantation
por: Gavriilaki, Eleni, et al.
Publicado: (2020)

Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine
por: Clemenceau, Beatrice, et al.
Publicado: (2021)

Antibody Response to Sars-Cov-2 Vaccination in Patients Following Allogeneic Hematopoietic Cell Transplantation
por: Cicin-Sain, Caroline, et al.
Publicado: (2021)

Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients
por: Le Bourgeois, Amandine, et al.
Publicado: (2021)

Chronic Graft-Versus-Host Disease (cGVHD) Exacerbation after Sars-Cov-2 Covid Vaccination
por: Trunk, Andrew D., et al.
Publicado: (2021)

Antibody Response to 2-Dose Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients
por: Maillard, Alexis, et al.
Publicado: (2021)

Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients
por: Minehart, Janna C., et al.
Publicado: (2021)

Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients
por: Harrington, Patrick, et al.
Publicado: (2021)

Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Jullien, Maxime, et al.
Publicado: (2021)

Serological Response Following BNT162b2 Anti-Sars-Cov-2 mRNA Vaccination in Hematopoietic Stem Cell Transplantation Patients
por: Attolico, Imma, et al.
Publicado: (2021)

Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2021)

Timing and Immune Status after Cellular Therapies Predict Response to COVID-19 Vaccines
por: Tamari, Roni, et al.
Publicado: (2021)

COVID-19 Vaccination after Allogeneic Stem Cell Transplantation: Real Word Data on Safety and Efficacy. a Single Center Experience.
por: Neagoie, Adela, et al.
Publicado: (2021)

Response to BNT162b2 Sars-Cov-2 Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
por: Saraceni, Francesco, et al.
Publicado: (2021)

Robust SARS-COV-2-specific T-cell immune memory persists long-term in immunocompetent individuals post BNT162b2 double shot
por: Papadopoulou, Anastasia, et al.
Publicado: (2022)

Pre-Emptive Use of Rituximab in Epstein–Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes
por: Papalexandri, Apostolia, et al.
Publicado: (2023)

Genetic justification of severe COVID-19 using a rigorous algorithm
por: Gavriilaki, Eleni, et al.
Publicado: (2021)

PB2226: THE ROLE OF COMPLEMENT IN THE IMMUNE RESPONSE OF SICKLE CELL DISEASE PATIENTS AFER COVID-19 VACCINATION
por: Varelas, C., et al.
Publicado: (2022)

Pre- and Post-transfusion Complement Activation in Transfusion-dependent β-thalassaemia
por: Gavriilaki, Eleni, et al.
Publicado: (2018)

P1311: LONG-TERM SAFETY AND EFFICACY OF EXTRACORPOREAL PHOTOPHERESIS AS EARLY SECOND-LINE TREATMENT FOR PATIENTS WITH STEROID-DEPENDENT OR REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE.
por: Gavriilaki, Eleni, et al.
Publicado: (2023)

Identification of Complement-Related Missense Variants in Pediatric Patients with Acute and Post COVID-19 Syndromes
por: Gavriilaki, Eleni, et al.
Publicado: (2021)

Genetic prediction of ICU hospitalization and mortality in COVID‐19 patients using artificial neural networks
por: Asteris, Panagiotis G., et al.
Publicado: (2022)

Outcomes of Patients with Hematologic Malignancies and COVID-19: Perspective of a Large Hematology Center in Greece
por: Spyridis, Nikolaos, et al.
Publicado: (2021)

PB2183: RELAPSE PREDICTS POOR OUTCOMES IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA POST ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Gavriilaki, E., et al.
Publicado: (2022)

Targeted Genotyping of MIS-C Patients Reveals a Potential Alternative Pathway Mediated Complement Dysregulation during COVID-19 Infection
por: Gavriilaki, Eleni, et al.
Publicado: (2022)

Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls
por: Gavriilaki, Eleni, et al.
Publicado: (2022)

PB1894: NPM1 MUTATED ACUTE MYELOID LEUKEMIA: THE CO-MUTATION PATTERNS MAY BE ASSOCIATED WITH PROGNOSIS
por: Varelas, Christos, et al.
Publicado: (2023)

Patient risk stratification and tailored clinical management of post‐transplant CMV‐, EBV‐, and BKV‐infections by monitoring virus‐specific T‐cell immunity
por: Papadopoulou, Anastasia, et al.
Publicado: (2021)

P1395: PENTAVALENT-SPECIFIC T-CELLS POST HAPLO-IDENTICAL TRANSPLANTATION FOR THE TREATMENT OF OPPORTUNISTIC INFECTIONS
por: Bousiou, Zoi, et al.
Publicado: (2023)

Blast Crisis of CML After TKI Discontinuation in a Patient With Previous Stable Deep Molecular Response: Is It Safe to Stop?
por: Papalexandri, Apostolia, et al.
Publicado: (2018)

Allogeneic Hematopoietic Cell Transplantation in Patients With Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria Clones: Time for a Change
por: Gavriilaki, Eleni, et al.
Publicado: (2020)

Risk Factors and Outcomes of Klebsiella pneumoniae Infection Before and After Allogeneic Hematopoietic Cell Transplantation
por: Gavriilaki, Eleni, et al.
Publicado: (2021)

A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity
por: Gavriilaki, Eleni, et al.
Publicado: (2020)

Thrombocytopenia in COVID-19: pathophysiology matters
por: Gavriilaki, Eleni, et al.
Publicado: (2020)

Identification of Respiratory Viral Infection in Hematopoietic Stem Cell Transplant Recipients - Impact on Non Relapse Mortality
por: Imlay-Gillespie, Louise, et al.
Publicado: (2015)

Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Hematopoietic Cell Transplantation and Cellular Therapies: A Retrospective Monocenter Real-Life Analysis
por: Gavriilaki, Eleni, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m59m25ldejr11eb45q51huttgl